Malignant ascites - Pipeline Insight, 2025
Description
DelveInsight’s, “Malignant ascites - Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Malignant ascites pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Malignant ascites: Overview
Ascites is the buildup of fluid in the space around the organs in the abdomen. When ascites is caused by cancer, it is called malignant ascites. The most common malignancies associated with the development of ascites include cancers of the colon/rectum, ovary, breast, lung, pancreas, liver, and lymphoma. Approximately 50% of patients with malignant ascites have peritoneal carcinomatosis with an additional 13% of patients having extensive liver metastases resulting in portal hypertension. Malignant ascites can develop through several mechanisms: blocked lymphatic channels as a result of malignancy, direct production of fluid into the peritoneal cavity by highly active cancers, and when “functional” cirrhosis develops in patients with extensive hepatic metastases resulting in portal hypertension. The development of malignant ascites carries a poor prognosis, with the median survival reported anywhere between 1 and 4 months.
""Malignant ascites - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Malignant ascites pipeline landscape is provided which includes the disease overview and Malignant ascites treatment guidelines. The assessment part of the report embraces, in depth Malignant ascites commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Malignant ascites collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Malignant ascites report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Malignant ascites Emerging Drugs
Further product details are provided in the report……..
Malignant ascites: Therapeutic Assessment
This segment of the report provides insights about the different Malignant ascites drugs segregated based on following parameters that define the scope of the report, such as:
Malignant ascites: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Malignant ascites therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Malignant ascites drugs.
Malignant ascites Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Malignant ascites: Overview
Ascites is the buildup of fluid in the space around the organs in the abdomen. When ascites is caused by cancer, it is called malignant ascites. The most common malignancies associated with the development of ascites include cancers of the colon/rectum, ovary, breast, lung, pancreas, liver, and lymphoma. Approximately 50% of patients with malignant ascites have peritoneal carcinomatosis with an additional 13% of patients having extensive liver metastases resulting in portal hypertension. Malignant ascites can develop through several mechanisms: blocked lymphatic channels as a result of malignancy, direct production of fluid into the peritoneal cavity by highly active cancers, and when “functional” cirrhosis develops in patients with extensive hepatic metastases resulting in portal hypertension. The development of malignant ascites carries a poor prognosis, with the median survival reported anywhere between 1 and 4 months.
""Malignant ascites - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Malignant ascites pipeline landscape is provided which includes the disease overview and Malignant ascites treatment guidelines. The assessment part of the report embraces, in depth Malignant ascites commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Malignant ascites collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Malignant ascites R&D. The therapies under development are focused on novel approaches to treat/improve Malignant ascites.
This segment of the Malignant ascites report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Malignant ascites Emerging Drugs
- SCB-313: Clover Biopharmaceuticals
Further product details are provided in the report……..
Malignant ascites: Therapeutic Assessment
This segment of the report provides insights about the different Malignant ascites drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Malignant ascites
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Malignant ascites: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Malignant ascites therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Malignant ascites drugs.
Malignant ascites Report Insights
- Malignant ascites Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Malignant ascites drugs?
- How many Malignant ascites drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Malignant ascites?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Malignant ascites therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Malignant ascites and their status?
- What are the key designations that have been granted to the emerging drugs?
- Clover Biopharmaceuticals
- YZY Biopharma
- Sorrento Therapeutics, Inc.
- Simcere
- PharmaCyte Biotech
- Linton Pharm
- SCB 313
- M 701
- CEA CAR-T cells
- Recombinant human endostatin
- Microencapsulated-P450-2B1-expressing-cells
- LP000
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Malignant ascites: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Malignant ascites – DelveInsight’s Analytical Perspective
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- SCB-313: Clover Biopharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Malignant ascites Key Companies
- Malignant ascites Key Products
- Malignant ascites- Unmet Needs
- Malignant ascites- Market Drivers and Barriers
- Malignant ascites- Future Perspectives and Conclusion
- Malignant ascites Analyst Views
- Malignant ascites Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
